Pharmaceuticals News and Research

RSS

Crown Bioscience, NRCMM partner to develop new immune-oncology experimental cancer models

Crown Bioscience, Inc., a leading global drug discovery and development service company with its R&D centers across the globe has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice and its commercial branch Nanjing Biotech Innovation Corporation, in Nanjing, Jiangsu Province, China.

6 Feb 2015

Isis receives $10 million from Biogen Idec to begin IND-supporting studies of ISIS-BIIB4 Rx

Isis Pharmaceuticals, Inc. announced today that it has earned a $10 million milestone payment from Biogen Idec for initiating the investigational new drug (IND)-supporting studies of ISIS-BIIB4 Rx.

5 Feb 2015

RXi closes exclusive global license agreement with Hapten Pharmaceuticals for Samcyprone

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering and developing innovative therapies addressing high-unmet medical needs, today announced the closing of its previously disclosed exclusive global license agreement for the therapeutic use of Samcyprone with Hapten Pharmaceuticals, LLC.

5 Feb 2015

MedImmune, University of Manchester sign new research collaboration

MedImmune, the global biologics research and development arm of AstraZeneca, and The University of Manchester have entered into a new research collaboration to generate cutting-edge protein formulation science.

5 Feb 2015

Biodegradable microstructures may help repair tissue, prevent heart failure

The delivery of tiny biodegradable microstructures to heart tissue damaged by heart attack may help repair the tissue and prevent future heart failure. A team led by cardiovascular researchers at the Medical College of Wisconsin bioengineered the microstructures to be the same size, shape and stiffness as adult heart muscle cells, or cardiomyocytes, with the goal of releasing biologically active peptides that act as cardioprotective agents.

5 Feb 2015

Galileo Analytics announces world-wide release of Galileo Thermometer

Galileo Analytics today announced the world-wide launch of Galileo Thermometer, a rapid-turn around platform for providing customized analysis of de-identified electronic health record data from the US and Europe.

4 Feb 2015

Study could lead to potential therapeutic targets to treat Ewing Sarcoma

A University of Colorado Cancer Center study published in the journal PLoS One finds alterations in expression of genes PIK3R3 and PTEN, more commonly observed in adult tumors, in the rare, young-adult bone cancer Ewing Sarcoma, potentially offering ways to improve therapy.

4 Feb 2015

COMBACTE-MAGNET project launched to study new treatment options for infections caused by MDR-GNB

Today 33 European academic partners and 5 pharmaceutical companies are launching a new project, COMBACTE-MAGNET, under the IMI antimicrobial resistance research programme New Drugs 4 Bad Bugs (ND4BB).

4 Feb 2015

Cphi partners with InformEx to launch new InformEx cGMP Zone at 2015 show

CPhI, the leading global sourcing event for the pharmaceutical industry, is partnering with InformEx to launch the new, InformEx cGMP Zone at the 2015 show (3-5th February in New Orleans).

4 Feb 2015

Isis announces top-line results from ISIS-PTP1B Rx Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. announced today top-line results from a Phase 2 study of ISIS-PTP1B Rx in patients with type 2 diabetes. In the Phase 2 study patients treated with ISIS-PTP1B Rx achieved statistically significant reductions in body weight and hemoglobin A1c (HbA1c).

3 Feb 2015

Using NMR to study influenza and TB: an interview with Dr. Tim Cross

In this interview, Tim Cross, Director of the NMR and MRI programs at the National High Magnetic Field Lab (NHMFL) in Tallahassee, Florida, talks about his research into protein structures in viruses and bacteria, and how the findings will affect medical research into disease prevention.

From Bruker BioSpin Division 3 Feb 2015

Immuron begins patient recruitment for Phase 2 clinical trial of IMM-124E NASH drug candidate

Australian biopharmaceutical company Immuron Limited has today announced a significant milestone in its Phase 2 clinical trial for non-alcoholic steatohepatitis (NASH) with the recruitment of its first two patients at Duke University in the United States. It is expected that further recruitment at Duke and other sites in the US and Australia will follow in early course.

3 Feb 2015

Serum Institute of India to use Genticel's Vaxiclase platform to develop pertussis vaccines

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, today announces that it has licensed its Vaxiclase technology to Serum Institute of India Ltd., for use as a component in acellular multivalent combination vaccines including pertussis antigens.

3 Feb 2015

Ildong Pharmaceutical to market BELVIQ (lorcaserin HCl) for weight management in South Korea

Arena Pharmaceuticals, Inc. today announced that Ildong Pharmaceutical Co., Ltd., has informed Arena that the Ministry of Food and Drug Safety has approved BELVIQ (lorcaserin HCl) for marketing for weight management in South Korea. Ildong will market and distribute BELVIQ in South Korea under its marketing and supply agreement with Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, or Arena GmbH.

3 Feb 2015

Mylan signs definitive agreement to acquire Famy Care's female health care businesses

Mylan Inc. today announced that it has, through its Indian subsidiary Mylan Laboratories Limited, signed a definitive agreement to acquire certain female health care businesses from Famy Care Limited, a specialty women's health care company with global leadership in generic oral contraceptive products (OCPs) for $750 million in cash plus additional contingent payments of up to $50 million.

2 Feb 2015

Study identifies genetic basis of drug toxicity in leukemia patients of East Asian ancestry

January 26, 2015) About 10 percent of young leukemia patients of East Asian ancestry inherit a gene variation that is associated with reduced tolerance of a drug that is indispensable for curing acute lymphoblastic leukemia (ALL), the most common childhood cancer.

2 Feb 2015

JOBS Act increases initial public offerings by 21%

The JOBS Act is doing its job and getting more startups to go public, according to a new study from the University at Buffalo School of Management.

2 Feb 2015

Altered dopamine signaling may contribute to autism

Newly discovered genetic variations linked to autism spectrum disorder (ASD) disrupt the function of the dopamine transporter, suggesting that altered dopamine signaling contributes to this common developmental condition, according to a Vanderbilt University-led research team.

31 Jan 2015

Project Spark to advance neuroprotective drug for schizophrenia-associated cognitive impairment

A public-private consortium led by the biotech Iproteos -based at Parc Científic de Barcelona (PCB)-, and comprised by the biopharmaceutical company Ascil-Biopharma, the Institute for Biomedical Research (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU) has launched a project to advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders.

31 Jan 2015

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

AbbVie released top-line Phase 3 results for its investigational, all-oral, ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan.

31 Jan 2015

Pharmaceuticals News and Research

Crown Bioscience, NRCMM partner to develop new immune-oncology experimental cancer models

Isis receives $10 million from Biogen Idec to begin IND-supporting studies of ISIS-BIIB4 Rx

RXi closes exclusive global license agreement with Hapten Pharmaceuticals for Samcyprone

MedImmune, University of Manchester sign new research collaboration

Biodegradable microstructures may help repair tissue, prevent heart failure

Galileo Analytics announces world-wide release of Galileo Thermometer

Study could lead to potential therapeutic targets to treat Ewing Sarcoma

COMBACTE-MAGNET project launched to study new treatment options for infections caused by MDR-GNB

Cphi partners with InformEx to launch new InformEx cGMP Zone at 2015 show

Isis announces top-line results from ISIS-PTP1B Rx Phase 2 study in type 2 diabetes patients

Using NMR to study influenza and TB: an interview with Dr. Tim Cross

Immuron begins patient recruitment for Phase 2 clinical trial of IMM-124E NASH drug candidate

Serum Institute of India to use Genticel's Vaxiclase platform to develop pertussis vaccines

Ildong Pharmaceutical to market BELVIQ (lorcaserin HCl) for weight management in South Korea

Mylan signs definitive agreement to acquire Famy Care's female health care businesses

Study identifies genetic basis of drug toxicity in leukemia patients of East Asian ancestry

JOBS Act increases initial public offerings by 21%

Altered dopamine signaling may contribute to autism

Project Spark to advance neuroprotective drug for schizophrenia-associated cognitive impairment

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence